Potency and selectivity of ERBB2-targeting antibody drug conjugates in vitro

被引：0
|
作者：
Peille, Anne-Lise
Holtorf, Kaja
Garcia, Pablo Anton
Obier, Nadine
Feger, Daniel
Metz, Thomas
Dempe, Sebastian
Fiebig, Heinz-Herbert
Ehlert, Jan
Vuaroqueaux, Vincent
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4708
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4708
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
    Yu, DH
    Hung, MC
    ONCOGENE, 2000, 19 (53) : 6115 - 6121
  • [2] Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
    Dihua Yu
    Mien-Chie Hung
    Oncogene, 2000, 19 : 6115 - 6121
  • [3] Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
    Ueno, Sho
    Kim, Min Woo
    Lee, Gibok
    Park, Yong Il
    Niidome, Takuro
    Lee, Ruda
    PHARMACEUTICS, 2020, 12 (06) : 1 - 15
  • [4] EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
    Cooper, Odelia
    Bonert, Vivien S.
    Rudnick, Jeremy
    Pressman, Barry D.
    Lo, Janet
    Salvatori, Roberto
    Yuen, Kevin C. J.
    Fleseriu, Maria
    Melmed, Shlomo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : E917 - E925
  • [5] The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
    Han, Siqi
    Meng, Yanchun
    Tong, Qing
    Li, Guangchao
    Zhang, Xunmin
    Chen, Yalin
    Hu, Shi
    Zheng, Lei
    Tan, Wenlong
    Li, Hui
    Chen, Yang
    Zhang, Ge
    Li, Bohua
    Guo, Yajun
    MABS, 2014, 6 (02) : 403 - 408
  • [6] On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
    Dovgan, Igor
    Ehkirch, Anthony
    Lehot, Victor
    Kuhn, Isabelle
    Koniev, Oleksandr
    Kolodych, Sergii
    Hentz, Alexandre
    Ripoll, Manon
    Ursuegui, Sylvain
    Nothisen, Marc
    Cianferani, Sarah
    Wagner, Alain
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
    Igor Dovgan
    Anthony Ehkirch
    Victor Lehot
    Isabelle Kuhn
    Oleksandr Koniev
    Sergii Kolodych
    Alexandre Hentz
    Manon Ripoll
    Sylvain Ursuegui
    Marc Nothisen
    Sarah Cianférani
    Alain Wagner
    Scientific Reports, 10
  • [8] The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases
    High, Peyton
    Guernsey, Cara
    Subramanian, Shraddha
    Jacob, Joan
    Carmon, Kendra S.
    PHARMACEUTICS, 2024, 16 (07)
  • [9] Targeting the tumor vasculature with antibody drug conjugates
    Hooper, Andrea T.
    Chang, Chao-Pei Betty
    Marquette, Kimberly
    Golas, Jonathon
    Lucas, Justin
    Nichols, Timothy
    Lucas, Judy
    Maria, Gavriil
    Rosfjord, Edward
    Xavier, Anton
    Scott, Nathan
    Jain, Sadhana
    Cao, Wei
    Leal, Mauricio
    Maderna, Andreas
    Guffroy, Magali
    Zheng, Xiang
    Tchistiakova, Lioudmila
    Loganzo, Frank
    Gerber, Hans-Peter
    May, Chad
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting moieties
    Han, Ji-Hye
    Park, Junghee
    Seo, Young-Woo
    Kim, Tae-Hyoung
    FEBS LETTERS, 2018, 592 (01): : 103 - 111
12345